Literature DB >> 20013309

Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.

Purushottam Kaushik1, Dhirendra K Singh, S Vinoth Kumar, Ashok K Tiwari, Gunjan Shukla, Shanker Dayal, Pallav Chaudhuri.   

Abstract

Brucella abortus, a gram negative, facultative intracellular pathogen causes brucellosis in many animal species and humans. Although live, attenuated vaccines are available against this infection, they suffer from certain limitations. Therefore, the development of an effective subunit vaccine against brucellosis is an area of intense research. The outer membrane proteins (OMPs) of Brucella species have been extensively studied for its immunogenicity and protective ability. We have investigated the potential of CpG ODN to enhance the immunogenicity and protective efficacy of recombinant 28 kDa outer membrane protein (rOMP28) of Brucella melitensis. The study demonstrated vigorous immunoglobulin G (IgG) response of OMP28. The administration of rOMP28 with CpG caused increased cell mediated immune response in terms of induced IgG2a, T-cell proliferation and up-regulation of type I cytokine expression. In contrast, the free antigen suppressed the interferon gamma (type I cytokine) production on in-vitro stimulation of spleenocytes. The result indicates the role of OMP28 in the down regulation of IFN-gamma production. Moreover, the B. abortus S-19 vaccinated mice showed highest production of IL-4 and IFN-gamma. The protective ability of the antigen was evaluated by systemic bacterial clearance after challenging the mouse with B. abortus 544 pathogen. The level of protection was significant in rOMP28+CpG treated mice but was lower than the required level. The results of the present study indicate that rOMP28 could be an immunogen capable of inducing both humoral and cellular immune response. The humoral response was biased towards Th1 type when it was co-administered with CpG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013309     DOI: 10.1007/s11259-009-9337-x

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  49 in total

1.  CpG DNA: a novel immunomodulator.

Authors:  A M Krieg
Journal:  Trends Microbiol       Date:  1999-02       Impact factor: 17.079

2.  Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria.

Authors:  K L Elkins; T R Rhinehart-Jones; S Stibitz; J S Conover; D M Klinman
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

Review 3.  Brucellosis vaccines: past, present and future.

Authors:  Gerhardt G Schurig; Nammalwar Sriranganathan; Michael J Corbel
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51.

Authors:  R Vemulapalli; Y He; S Cravero; N Sriranganathan; S M Boyle; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Liposomised recombinant ribosomal L7/L12 protein protects BALB/c mice against Brucella abortus 544 infection.

Authors:  A I Mallick; H Singha; P Chaudhuri; Ahmad Nadeem; Shadab Ahmad Khan; Khurshid Ahmad Dar; M Owais
Journal:  Vaccine       Date:  2007-01-25       Impact factor: 3.641

7.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

8.  Brucella ribosomal protein L7/L12 is a major component in the antigenicity of brucellin INRA for delayed-type hypersensitivity in brucella-sensitized guinea pigs.

Authors:  G Bachrach; M Banai; S Bardenstein; G Hoida; A Genizi; H Bercovier
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

9.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.

Authors:  L B Tabatabai; G W Pugh
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

View more
  9 in total

1.  Evaluation of immunogenicity and protective efficacy of a liposome containing Brucella abortus S19 outer membrane protein in BALB/c mice.

Authors:  F Mukherjee; A Prasad; V S Bahekar; S K Rana; L Rajendra; G K Sharma; V A Srinivasan
Journal:  Iran J Vet Res       Date:  2016       Impact factor: 1.376

2.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 3.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

4.  Vaccination with Brucella abortus recombinant in vivo-induced antigens reduces bacterial load and promotes clearance in a mouse model for infection.

Authors:  Jake E Lowry; Dale D Isaak; Jack A Leonhardt; Giulia Vernati; Jessie C Pate; Gerard P Andrews
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

5.  Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection.

Authors:  Simei Fu; Jie Xu; Xianbo Li; Yongfei Xie; Yefeng Qiu; Xinying Du; Shuang Yu; Yaoxia Bai; Yanfen Chen; Tongkun Wang; Zhoujia Wang; Yaqing Yu; Guangneng Peng; Kehe Huang; Liuyu Huang; Yufei Wang; Zeliang Chen
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

6.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  Protective effects of recombinant Brucella abortus Omp28 against infection with a virulent strain of Brucella abortus 544 in mice.

Authors:  Jeong Ju Lim; Dong Hyeok Kim; Jin Ju Lee; Dae Geun Kim; Wongi Min; Hu Jang Lee; Man Hee Rhee; Suk Kim
Journal:  J Vet Sci       Date:  2012-09       Impact factor: 1.672

Review 8.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

Review 9.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.